This page shows the latest asthma drug news and features for those working in and with pharma, biotech and healthcare.
cancer as well as autoimmune indications, headed by a drug for solid tumours that is in a phase 1 trial. ... drug Dupixent (dupilumab) – but also failures such as dengue vaccine Dengvaxia and underperforming cholesterol drug Praluent (alirocumab).
Demonstrated significant benefits in uncontrolled asthma patients. Novartis has unveiled positive phase 3 data for its dual combination asthma drug QMF149, strengthening its case for approval with regulators. . ... QMF149 also met the secondary endpoint
Sanofi has had a difficult few years following the loss of patent protection for its former diabetes cash cow Lantus (insulin glargine), with some pipeline successes – notably atopic dermatitis and asthma ... There have been some failures as well
Well, twice in recent weeks I’ve worked with companies in chronic diseases – diabetes and asthma. ... Both began their thinking worrying about how to evolve their product – in the first case a continuous blood sugar monitor, in the second an asthma
Key Q3 drivers include Shingrix vaccine and asthma drug Nucala. GlaxoSmithKline has raised its profit forecast for the second consecutive quarter thanks to the strong sales of its shingles vaccine Shingrix ... The drug is on track to be filed for
Drug on track to meet blockbuster forecasts. Sanofi and Regeneron’s Dupixent will now enter the asthma market in Europe, the new expansion confirming its blockbuster profile. ... Already approved in atopic dermatitis, the drug can now be used an add-on
More from news
Approximately 2 fully matching, plus 115 partially matching documents found.
This was the turning point for the development programme.”. The late nights interrogating the science and unpicking data sets prompted the switch from a drug for the broad asthma community to ... a therapy targeted at a subtype representing around 10%
Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug (AZD2098)
In fact, it’s safe to say most C-suite drug executives would hardly shed a tear upon news of Obamacare’s swift demise. ... To cite just one example, patients with financial need get an 85% discount on the popular asthma drug Advair, and that’s by
In April 2013, Novartis was denied patent protection for its cancer drug, Glivec, by the Indian Supreme Court. ... This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV)
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002. ... Discovery. Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John's experience in ion channels,
the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...